Entrada Therapeutics, Inc. (TRDA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TRDA currently has 41.8M outstanding shares. with significant dilution risk as 31.3M authorized shares could dilute existing holders by 74.8%. The company has significantly diluted shareholders by 34.93% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 41.8M shares outstanding |
42M | 31M |
| Nov 06, 2025 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to $400,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units, and also covers the offer and sale of up to $150,000,000 of common stock under a sales agreement with TD Securities (USA) LLC. |
38M | 49M |
| Nov 06, 2025 |
10-Q filing | 41.5M shares outstanding |
41M | 26M |
| Aug 06, 2025 |
10-Q filing | 41.3M shares outstanding |
41M | 26M |
| May 08, 2025 |
10-Q filing | 41.1M shares outstanding |
41M | 26M |
| Feb 27, 2025 |
10-K filing | 37.3M shares outstanding |
37M | 26M |
| Nov 05, 2024 |
10-Q filing | 40.6M shares outstanding |
41M | 26M |
| Aug 13, 2024 |
10-Q filing | 35.5M shares outstanding |
36M | 26M |
| May 07, 2024 |
10-Q filing | 33.5M shares outstanding |
33M | 26M |
| Mar 13, 2024 |
10-K filing | 33.1M shares outstanding |
33M | 26M |
| Nov 07, 2023 |
10-Q filing | 33.3M shares outstanding |
33M | 26M |
| Aug 08, 2023 |
10-Q filing | 33.2M shares outstanding |
33M | 26M |
| May 10, 2023 |
10-Q filing | 32.4M shares outstanding |
32M | 26M |
| Mar 06, 2023 |
10-K filing | 31.3M shares outstanding |
31M | 26M |
| Feb 09, 2023 |
8-K filing: Entrada closed the sale of 1,618,613 shares of its common stock to Vertex for $26.3 million at $16.26 per share. ($26.3M proceeds) |
31M | 26M |
| Dec 08, 2022 |
8-K filing: Entrada Therapeutics, Inc. entered into a Strategic Collaboration and License Agreement with Vertex Pharmaceuticals Incorporated, which includes an equity investment by Vertex of approximately $26.3 million in Entrada's common stock through a stock purchase agreement. ($26.3M proceeds) |
31M | 26M |
| Nov 07, 2022 |
10-Q filing | 31.3M shares outstanding |
31M | 26M |
| Nov 01, 2022 |
S-3 filing: Entrada Therapeutics, Inc. is filing an S-3 registration statement to offer up to $400,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. |
31M | 26M |
| Aug 11, 2022 |
10-Q filing | 31.3M shares outstanding |
31M | 8.6M |
| May 12, 2022 |
10-Q filing | 31.2M shares outstanding |
31M | 8.6M |
| Mar 15, 2022 |
10-K filing | 31.3M shares outstanding |
31M | 8.6M |
| Dec 09, 2021 |
10-Q filing | 31.2M shares outstanding |
31M | 8.6M |
| Oct 25, 2021 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock with an additional option for underwriters to purchase shares, aiming to raise funds for clinical development, research, and general corporate purposes. |
1.6M | 8.6M |
| Oct 08, 2021 |
S-1 filing: This is an initial public offering of shares of common stock of Entrada Therapeutics, Inc. |
12M | 0 |